CTLA4 and posterior cortical atrophy: These findings are exciting, especially considering that there are still many PCa patients who do not respond to anti-PD1 or anti-CTLA-4 therapy, in part because PCa itself has low immune infiltration and in part because tumor cells may achieve immune escape through other pathways.